OUR RESOURCES

FEATURED CONTENT

Why Age-Tech is the new Fin-Tech

1. Fin-tech start-ups have exploded in value to +$250B, annual financing growing 20x to $40B 2. The UK has over-performed in Fin-tech by harnessing London’s role as global finance epicentre and ‘tech’ centre, and via depth across all financing stages...

Read More

Vesalius Biocapital III Announced the Final Close of EUR 120 million Fund

Following the announcement from Vesalius Biocapital we spoke to Marc Lohrmann, Venture Partner, to get a better understanding of who they are, what they're focused on and their plans for the future. 1. For our community members who may not be fully a...

Read More

CASE STUDY

Addex prepares PD-LID programme for 2019 Phase 3 registration trial

Key findings: Switzerland-based Addex Therapeutics is preparing its lead ca...

Read More

World-first accreditation to out-of-this-world applications for Oxehealth’s vital signs technology

Key learnings: Oxford-based Oxehealth has secured medical device accreditat...

Read More

Gates Foundation funding for DelSiTech’s silica-based drug delivery technology

Key learnings: DelSiTech has been awarded significant grant funding from th...

Read More
View More

EXPERT INSIGHT

Medical devices: Investment trends, challenges and opportunities

In the current climate there are several major challenges or trends in inve...

Read More

How to pitch to a life science VC investor

Pitching a venture capital fund is not an easy exercise for many entreprene...

Read More

Bridging the investment gap between drug discovery and clinical development in oncology

Established in 2012, the CRT Pioneer Fund (CPF), managed by Sixth Element C...

Read More
View More

INVESTORVIEW

Investorview: Propelling life science innovation from pre-seed to patients

Denmark’s Novo Seeds was established in 2007 in order to identify promising...

Read More

Investorview: Ingredients for growth in life sciences investment

Industrifonden is an evergreen venture capital fund with headquarters in St...

Read More

Investorview: Why people are key in life science investments

Since it was founded in 1996, European venture capital firm HealthCap has i...

Read More
View More

LSX REPORT

Medical devices: Investment trends, challenges and opportunities

In the current climate there are several major challenges or trends in inve...

Read More

How to pitch to a life science VC investor

Pitching a venture capital fund is not an easy exercise for many entreprene...

Read More

Bridging the investment gap between drug discovery and clinical development in oncology

Established in 2012, the CRT Pioneer Fund (CPF), managed by Sixth Element C...

Read More
View More

WHITE PAPER

Medius Deal Watch: September-October 2018

There was much speculation last year that the US tax cuts that favoured the...

Read More

Infographic: C-suite challenges in life sciences 2018

In early 2017, LSX, formerly Biotech and Money, published the inaugural Inv...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More
View More

VIDEO

Interview with Avacta Group's Alastair Smith

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Interview with HemoGenyx's Vladislav Sandler

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Interview with Inmedix’s Andrew J. Holman

Andrew J. Holman, Co-Founder and Chief Executive Officer at Inmedix, talks ...

Read More
View More

EVENT

Q&A: Fostering a start-up and growth ecosystem in New Jersey

Jose Lozano, President and Chief Executive Officer at Choose New Jersey, ou...

Read More

The Future of Digital Health: Q&A with Capricorn Venture Partners’ Marc Lambrechts

As new technologies look to play an ever-increasing role in addressing heal...

Read More

Investing in Early-Stage Innovation: Q&A with Sanofi Ventures’ Laia Crespo

How are established investors working to foster innovation in today’s biote...

Read More
View More

WEBINAR

Advanced therapies: Gaining market access in a challenging European environment

Listen to the final session in Phacilitate and LSX's (formerly known as Bio...

Read More

Overcoming commercialisation challenges in advanced therapies

Learn more about the commercialisation of advanced therapies in the on-dema...

Read More

Why whistleblowing should be a boardroom issue in life sciences

On-demand webinar now available New EU-wide whistleblowing regulations have...

Read More
View More